Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.
Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group. Durelli L, et al. Among authors: barbero p. Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781. Expert Opin Biol Ther. 2009. PMID: 19278300 Clinical Trial.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group. Durelli L, et al. Among authors: barbero p. J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25. J Neurol. 2008. PMID: 18825438 Clinical Trial.
Interferon-beta dose and efficacy: the OPTIMS study.
Durelli L, Oggero A, Verdun E, Barbero P, Pipieri A, Isoardo G, Ricci A, Clerico M, Bradac G, Bergamasco B, Bergui M. Durelli L, et al. Among authors: barbero p. Neurol Sci. 2001 Apr;22(2):201-3. doi: 10.1007/s100720170024. Neurol Sci. 2001. PMID: 11603627
MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis.
Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Rivoiro C, Ferrero C, Picco E, Ripellino P, Giuliani G, Montanari E, Clerico M; Italian Multiple Sclerosis Study Group. Durelli L, et al. Among authors: barbero p. J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):646-51. doi: 10.1136/jnnp.2007.130229. Epub 2007 Nov 6. J Neurol Neurosurg Psychiatry. 2008. PMID: 17986500 Clinical Trial.
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M; Independent Comparison of Interferon (INCOMIN) Trial Study Group. Durelli L, et al. Among authors: barbero p. Lancet. 2002 Apr 27;359(9316):1453-60. doi: 10.1016/s0140-6736(02)08430-1. Lancet. 2002. PMID: 11988242 Clinical Trial.
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L. Clerico M, et al. Among authors: barbero p. Expert Opin Drug Saf. 2017 Aug;16(8):963-972. doi: 10.1080/14740338.2017.1346082. Epub 2017 Jul 5. Expert Opin Drug Saf. 2017. PMID: 28641055 Free article. Review.
155 results